Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Societe Francaise de Rhumatologie
With
Assistance Publique - Hôpitaux de Paris
University Hospital, Toulouse
Design :
Randomised, controlled trial within the e-cohort population of the French ART registry (observational study)
Target population :
All participants to the e-cohort of the French ART Registry (Rheumatoid Arthritis and anti-TNF)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
All patients included in the French ART Registry (rheumatoid arthritis and anti-TNF) and participating to the e-cohort.
Adult patients with RA,
Patient in whom the specialist physician decides to start treatment with an anti-TNF drug, regardless of the treatment line and regardless of the anti-TNF, including infliximab, adalimumab, etanercept, certolizumab and golimumab, and their respective biosimilar according to their arrival on the market
Clinicians (hospital-based and private practice) who agree to adhere to the yearly renewal of the hospital prescription
You may not be if
Patient already treated by the same anti-TNF in the past (same drug)
